Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats

Tomoko Yoshikawa, Takuya Kishi, keisuke shinohara, Ko Takesue, Risa Shibata, Noriyuki Sonoda, Toyoshi Inoguchi, Kenji Sunagawa, Hiroyuki Tsutsui, Yoshitaka Hirooka

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

To prevent cardiovascular events in patients with diabetes mellitus (DM), it is essential to reduce arterial pressure (AP). Sodium-glucose cotransporter 2 inhibitor (SGLT2i) prevents cardiovascular events via the depressor response in patients with DM. In the present study, we examined whether SGLT2i ameliorates AP lability in DM rats. Ten-week-old male Sprague-Dawley rats were administered a single intravenous injection of streptozotocin (50 mg kg-1) and were divided into three groups treated with low-dose SGLT2i, vehicle (VEH) or subcutaneously implanted insulin pellets (SGLT2i, VEH and Insulin group, respectively) for 14 days. SGLT2i reduced blood glucose, but its effect was lower than that of insulin. The telemetered mean AP at the end of the experiment did not differ among the SGLT2i, Insulin and VEH groups (83±7 vs. 98±9 vs. 90±8 mm Hg, respectively, n=5 for each). The standard deviation of AP as the index of lability was significantly smaller during the active period in the SGLT2i group than in the VEH group (5.6±0.5 vs. 7.0±0.7 mm Hg, n=5 for each, P<0.05). Sympathetic nerve activity during the active period was significantly lower in the SGLT2i group than in the VEH group. Baroreflex sensitivity (BRS) was significantly higher in the SGLT2i group than in the VEH group. The standard deviation of AP and sympathoexcitation did not differ between the Insulin and VEH groups. In conclusion, SGLT2i at a non-depressor dose ameliorated the AP lability associated with sympathoinhibition during the active period and improved the BRS in streptozotocin-induced DM rats.

Original languageEnglish
Pages (from-to)646-651
Number of pages6
JournalHypertension Research
Volume40
Issue number7
DOIs
Publication statusPublished - Jul 1 2017

Fingerprint

Sodium-Glucose Transport Proteins
Streptozocin
Arterial Pressure
Insulin
Diabetes Mellitus
Baroreflex
Experimental Diabetes Mellitus
Intravenous Injections
Sprague Dawley Rats
Blood Glucose

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats. / Yoshikawa, Tomoko; Kishi, Takuya; shinohara, keisuke; Takesue, Ko; Shibata, Risa; Sonoda, Noriyuki; Inoguchi, Toyoshi; Sunagawa, Kenji; Tsutsui, Hiroyuki; Hirooka, Yoshitaka.

In: Hypertension Research, Vol. 40, No. 7, 01.07.2017, p. 646-651.

Research output: Contribution to journalArticle

Yoshikawa, Tomoko ; Kishi, Takuya ; shinohara, keisuke ; Takesue, Ko ; Shibata, Risa ; Sonoda, Noriyuki ; Inoguchi, Toyoshi ; Sunagawa, Kenji ; Tsutsui, Hiroyuki ; Hirooka, Yoshitaka. / Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats. In: Hypertension Research. 2017 ; Vol. 40, No. 7. pp. 646-651.
@article{ace9f2bd5f814783948e8f1cf1401ca5,
title = "Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats",
abstract = "To prevent cardiovascular events in patients with diabetes mellitus (DM), it is essential to reduce arterial pressure (AP). Sodium-glucose cotransporter 2 inhibitor (SGLT2i) prevents cardiovascular events via the depressor response in patients with DM. In the present study, we examined whether SGLT2i ameliorates AP lability in DM rats. Ten-week-old male Sprague-Dawley rats were administered a single intravenous injection of streptozotocin (50 mg kg-1) and were divided into three groups treated with low-dose SGLT2i, vehicle (VEH) or subcutaneously implanted insulin pellets (SGLT2i, VEH and Insulin group, respectively) for 14 days. SGLT2i reduced blood glucose, but its effect was lower than that of insulin. The telemetered mean AP at the end of the experiment did not differ among the SGLT2i, Insulin and VEH groups (83±7 vs. 98±9 vs. 90±8 mm Hg, respectively, n=5 for each). The standard deviation of AP as the index of lability was significantly smaller during the active period in the SGLT2i group than in the VEH group (5.6±0.5 vs. 7.0±0.7 mm Hg, n=5 for each, P<0.05). Sympathetic nerve activity during the active period was significantly lower in the SGLT2i group than in the VEH group. Baroreflex sensitivity (BRS) was significantly higher in the SGLT2i group than in the VEH group. The standard deviation of AP and sympathoexcitation did not differ between the Insulin and VEH groups. In conclusion, SGLT2i at a non-depressor dose ameliorated the AP lability associated with sympathoinhibition during the active period and improved the BRS in streptozotocin-induced DM rats.",
author = "Tomoko Yoshikawa and Takuya Kishi and keisuke shinohara and Ko Takesue and Risa Shibata and Noriyuki Sonoda and Toyoshi Inoguchi and Kenji Sunagawa and Hiroyuki Tsutsui and Yoshitaka Hirooka",
year = "2017",
month = "7",
day = "1",
doi = "10.1038/hr.2017.14",
language = "English",
volume = "40",
pages = "646--651",
journal = "Hypertension Research",
issn = "0916-9636",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats

AU - Yoshikawa, Tomoko

AU - Kishi, Takuya

AU - shinohara, keisuke

AU - Takesue, Ko

AU - Shibata, Risa

AU - Sonoda, Noriyuki

AU - Inoguchi, Toyoshi

AU - Sunagawa, Kenji

AU - Tsutsui, Hiroyuki

AU - Hirooka, Yoshitaka

PY - 2017/7/1

Y1 - 2017/7/1

N2 - To prevent cardiovascular events in patients with diabetes mellitus (DM), it is essential to reduce arterial pressure (AP). Sodium-glucose cotransporter 2 inhibitor (SGLT2i) prevents cardiovascular events via the depressor response in patients with DM. In the present study, we examined whether SGLT2i ameliorates AP lability in DM rats. Ten-week-old male Sprague-Dawley rats were administered a single intravenous injection of streptozotocin (50 mg kg-1) and were divided into three groups treated with low-dose SGLT2i, vehicle (VEH) or subcutaneously implanted insulin pellets (SGLT2i, VEH and Insulin group, respectively) for 14 days. SGLT2i reduced blood glucose, but its effect was lower than that of insulin. The telemetered mean AP at the end of the experiment did not differ among the SGLT2i, Insulin and VEH groups (83±7 vs. 98±9 vs. 90±8 mm Hg, respectively, n=5 for each). The standard deviation of AP as the index of lability was significantly smaller during the active period in the SGLT2i group than in the VEH group (5.6±0.5 vs. 7.0±0.7 mm Hg, n=5 for each, P<0.05). Sympathetic nerve activity during the active period was significantly lower in the SGLT2i group than in the VEH group. Baroreflex sensitivity (BRS) was significantly higher in the SGLT2i group than in the VEH group. The standard deviation of AP and sympathoexcitation did not differ between the Insulin and VEH groups. In conclusion, SGLT2i at a non-depressor dose ameliorated the AP lability associated with sympathoinhibition during the active period and improved the BRS in streptozotocin-induced DM rats.

AB - To prevent cardiovascular events in patients with diabetes mellitus (DM), it is essential to reduce arterial pressure (AP). Sodium-glucose cotransporter 2 inhibitor (SGLT2i) prevents cardiovascular events via the depressor response in patients with DM. In the present study, we examined whether SGLT2i ameliorates AP lability in DM rats. Ten-week-old male Sprague-Dawley rats were administered a single intravenous injection of streptozotocin (50 mg kg-1) and were divided into three groups treated with low-dose SGLT2i, vehicle (VEH) or subcutaneously implanted insulin pellets (SGLT2i, VEH and Insulin group, respectively) for 14 days. SGLT2i reduced blood glucose, but its effect was lower than that of insulin. The telemetered mean AP at the end of the experiment did not differ among the SGLT2i, Insulin and VEH groups (83±7 vs. 98±9 vs. 90±8 mm Hg, respectively, n=5 for each). The standard deviation of AP as the index of lability was significantly smaller during the active period in the SGLT2i group than in the VEH group (5.6±0.5 vs. 7.0±0.7 mm Hg, n=5 for each, P<0.05). Sympathetic nerve activity during the active period was significantly lower in the SGLT2i group than in the VEH group. Baroreflex sensitivity (BRS) was significantly higher in the SGLT2i group than in the VEH group. The standard deviation of AP and sympathoexcitation did not differ between the Insulin and VEH groups. In conclusion, SGLT2i at a non-depressor dose ameliorated the AP lability associated with sympathoinhibition during the active period and improved the BRS in streptozotocin-induced DM rats.

UR - http://www.scopus.com/inward/record.url?scp=85018525066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018525066&partnerID=8YFLogxK

U2 - 10.1038/hr.2017.14

DO - 10.1038/hr.2017.14

M3 - Article

C2 - 28202943

AN - SCOPUS:85018525066

VL - 40

SP - 646

EP - 651

JO - Hypertension Research

JF - Hypertension Research

SN - 0916-9636

IS - 7

ER -